Vogenx Inc (VOGX) Stock
Vogenx stock price chart
VOGX stock quote & key statistics
Vogenx annual financials
Income statement →| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2025 | $0 | -$1.4M | — |
| FY2024 | $0 | -$2.2M | — |
Fiscal year ending December 31. Source: company filings via EODHD.
About Vogenx Inc
Vogenx, Inc. operates as a clinical-stage drug development company that develops therapeutics for metabolic including post-bariatric hypoglycemia, or PBH, and gastroparesis. Its products include drugs, such as Mizagliflozin and VGX-2857. It also offers VGX-001, a human monoclonal antibody for the treatment of type 1 diabetes (T1D). It caters to healthcare providers, physicians and third-party payors in the United States. The company was incorporated in 2021 and is based in Raleigh, North Carolina.
Vogenx stock FAQ
What is the Vogenx stock ticker symbol?
Vogenx Inc trades on the NASDAQ under the ticker symbol VOGX.
What sector and industry is Vogenx in?
Vogenx Inc is classified in the Healthcare sector, Biotechnology industry.
How many employees does Vogenx have?
Vogenx Inc has about 4 full-time employees.
What were Vogenx's revenue and earnings last fiscal year?
Vogenx reported revenue of $0 and net income of -$1.4M in fiscal 2025.
When did Vogenx go public?
Vogenx stock began trading on August 12, 2026.
Biotechnology stocks
All Healthcare stocks →- ACADACADIA Pharmaceuticals
- ALNYAlnylam
- ARWRArrowhead Pharmaceuticals
- ASNDAscendis Pharma A/S
- BMRNBioMarin Pharmaceutical
- CAICaris Life Sciences
- CORTCorcept Therapeutics
- EXELExelixis
- FTREFortrea
- HALOHalozyme Therapeutics
- HRMYHarmony Biosciences
- INCYIncyte
- IONSIonis Pharmaceuticals
- JAZZJazz Pharmaceuticals
- MDGLMadrigal Pharmaceuticals
- MRNAModerna
- NVAXNovavax
- PTCTPTC Therapeutics
- RAREUltragenyx Pharmaceutical
- REGNRegeneron
- RPRXRoyalty Pharma
- SRPTSarepta Therapeutics
- TECHBio-Techne
- VRTXVertex